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Polycystic kidney disease (PKD) accounts for 7–10% of all
dialyzed renal insufficient patients. Accumulation of specific
guanidino compounds (GCs) has been related to
neurological, cardiovascular, hematological, and
immunological complications of renal failure. In this study,
we investigate whether the PKD/Mhm rat model can be used
as a biochemical model for human PKD. For the validation
of the rat model, we performed the first detailed evaluation
of the concentrations of GCs in serum and urine of patients
with PKD in addition to the GC patterns in the plasma,
urine, and tissues of the PKD/Mhm rat model. The GCs were
determined after separation on a cation exchange resin and
fluorescence detection. The GC levels and changes observed
in blood and urine of patients with PKD are comparable
with those found in patients with renal insufficiency due to
different etiologies. The PKD/Mhm rat model can be used as a
biochemical model for human PKD as the obvious increases
of urea, guanidinosuccinic acid, creatinine, guanidine,
methylguanidine, and NGNG-dimethylarginine (symmetrical
dimethylarginine) seen in blood of oldest heterozygous and
younger homozygous PKD rats were largely within the same
range as those found in the studied human PKD population,
especially in patients with a glomerular filtration rate below
60 ml/min/1.73 m2. The decreased levels of plasma
guanidinoacetic acid seen at end-stage renal disease in
homozygous and oldest heterozygous rats were also
observed in serum of patients with a glomerular filtration
rate below 20 ml/min/1.73 m2. The PKD/Mhm rat model has,
besides similar disease characteristics with human PKD,
comparable GC alterations.
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Polycystic kidney disease (PKD) is a frequent cause of end-
stage renal failure in adults. Autosomal dominant PKD is the
most common form of PKD and presents in one of 800 live
births. PKD accounts for 7 to 10% of all dialyzed patients
with renal insufficiency. The disease, mainly caused by
truncating mutations in the PKD1 and PKD2 genes, is
characterized by cystic enlargement of both kidneys. In
addition, cysts in the liver and pancreas, and increased risk
for aortic and intracerebral aneurysms, are present.1
Different guanidino compounds (GCs) were reported as
possible uremic toxins that could play a role in the
symptomatology seen in patients with renal failure.2–7
Guanidinosuccinic acid (GSA), guanidine (G), methylguani-
dine (MG), and creatinine (CTN) are significantly increased
in the serum, urine, cerebrospinal fluid, and different brain
regions of patients with renal failure and have been reported
as potential uremic toxins.8–10 Accumulation of GSA, MG, G,
and CTN possibly contributes to neurological symptoms of
uremia.2,3,11 NGNG0-dimethylarginine (ADMA) was pre-
viously shown to be doubled in serum of non-dialyzed
patients with chronic renal insufficiency.12 This latter GC is
an inhibitor of NO synthase and could play a role in
hypertension and increased tension in cerebral arteries.6,13–15
Some GCs have been related to leukocyte activation and
might in this way be related to uremic vascular disease.16 In
addition, there is a decrease of some GCs like guanidinoacetic
acid (GAA) and homoarginine (Harg) in patients with renal
failure.12
In several animal models for renal disease, altered GC
concentration patterns, corresponding more or less to those
found in man, have been reported.17–19 Several mouse strains,
in which PKD is transmitted in an autosomal recessive
pattern, provided insights into the pathogenesis of renal cyst
formation.20,21 The PKD/Mhm rat model is related to a
spontaneous mutation in the Sprague–Dawley strain, with
autosomal dominant transmission.22 PKD in the PKD/Mhm
rat appeared to be due to mutation in a novel gene, PKDr1.23
Homozygous PKD/Mhm animals develop massive renal
enlargement leading to death within the first postnatal
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month. The two kidneys are usually injured to the same
extent. Heterozygous animals of both sexes display slowly
progressive renal cystic disease, but male heterozygous
animals manifest a significantly more severe form of the
disease than female animals.21,24 Previous studies reported
different features of this rat model, which are similar to the
characteristics of human with PKD.1,22,25,26 However, there
are no data available showing that complex biochemical
processes, such as the uremic retention pattern of GCs, are
similar to the human equivalent.
This is the first detailed study evaluating the concentra-
tions of GCs in a population of renal insufficient individuals
consisting exclusively of non-dialyzed PKD patients. In
addition, we studied for the first time the GC patterns in
the plasma, urine, and tissues of the PKD rat model PKD/
Mhm. The observed profiles of the PKD rats were compared
with those obtained in patients with PKD. The validation of
the PKD rat model in this area is useful for future research on
pathobiochemistry and pathophysiology of the PKD, con-
sidering the importance of these compounds in symptoms of
renal failure.
RESULTS
Concentration of GCs in PKD patients
Serum. Significantly increased levels of urea, GSA (which
is metabolically related to urea), CTN, ADMA, and NGNG-
dimethylarginine (SDMA) were found in the serum of PKD
patients (Table 1a). Increased levels of G, MG, a-keto-d-
guanidinovaleric acid (a-Keto-d-GVA), a-N-acetylarginine
(a-NAA), and g-guanidinobutyric acid (g-GBA) were also
observed in patients. Serum GAA was significantly decreased
in patients with a glomerular filtration rate (GFR) below
20 ml/min/1.73 m2.
The latter increases progressed with decreasing GFR: urea
(R¼0.767; Po0.001), SDMA (R¼0.751; Po0.001),
CTN (R¼0.740; Po0.001), G (R¼0.726; Po0.001),
GSA (R¼0.700; Po0.001), argininic acid (R¼0.695;
Po0.001), and a-NAA (R¼0.510; Po0.01). Although no
significant differences in Harg were observed as compared
with controls, Harg decreased progressively with increasing
renal dysfunction (R¼ 0.605; Po0.001).
Urine. Practically, only in the studied PKD patients with
a GFR below 20 ml/min/1.73 m2, significant changes were
observed: significantly increased levels of GSA, G, and MG
next to decreased urinary excretion levels of GAA, ADMA,
a–Keto-d-GVA, a-NAA, and g-GBA. The urinary excretion
levels of the other GCs did not change (Table 1b).
The urinary excretion levels of GSA and MG increased
progressively with decreasing GFR, whereas those of GAA
and ADMA decreased progressively with renal dysfunction
(respectively, R¼0.589, 0.670, 0.611, 0.525 and
P¼ 0.002, o0.001, ¼ 0.001, ¼ 0.01)
Concentration of GCs in PKD rats
Plasma. Urea and GSA were progressively retained in
plasma during renal failure in homozygous and heterozygous
PKD rats (Table 2a and b). Further, a clear retention of CTN
and g-GBA was observed in all homozygous and hetero-
zygous animals. Plasma concentration of G, MG, a-Keto-d-
GVA, and SDMA was increased in homozygous and in oldest
heterozygous rats. Plasma GAA was clearly decreased in
homozygous rats with end-stage renal failure and in oldest
heterozygous rats. Creatine (CT) was significantly lower in
plasma of oldest homozygous rats and in heterozygous rats
aged 10 and 18 months. A progressive decrease of plasma
arginine (Arg) was observed in homozygous animals.
Table 1a | GCs (lM) and urea (mM) in serum of PKD patients and controls
Serum
Controls
n=9
GFR: normal–60 ml/min/1.73m2
n=9
Controls
n=7
GFR: 20–60 ml/min/1.73 m2
n=7
Controls
n=11
GFR: o20 ml/min/1.73 m2
n=11
aKetodGVA o0.035 o0.035 o0.035 0.1570.04 o0.035 0.2270.03
GSA 0.2870.09 0.3670.04 0.2970.06 1.3070.41* 0.2870.05 11.071.8***,a
CT 40.5710.4 38.475.5 36.377.5 34.876.4 36.378.3 34.479.4
GAA 2.7770.33 2.0770.14 2.2970.30 2.2270.29 2.4570.12 1.8370.19*
a-NAA o0.025 0.5570.06 o0.025 0.7370.03 o0.025 0.8870.12
ArgA o0.025–0.12 0.0570.01 0.1670.05 0.1570.03 0.1870.04 0.2870.04
b-GPA o0.013 o0.013 o0.013 o0.013 o0.013 o0.013
CTN 68.075.9 66.976.0 72.676.6 153727* 66.874.4 519766***,a
g-GBA o0.013 o0.013–0.05 o0.013 0.0670.01 o0.013 o0.013–0.1
Arg 10377.4 10777.8 11278.2 12576.6 11675.9 11479.9
Harg 1.4070.22 2.0770.24 1.5570.20 1.3670.09 1.6370.22 1.1670.11
G o0.06 0.2270.03 o0.06 0.4170.06 o0.06 1.3470.16
MG o0.02 o0.02 o0.02 0.0870.02 o0.02 1.0170.46
ADMA 0.3970.03 0.6870.05*** 0.4970.04 0.7070.05** 0.4570.02 0.8570.06***
SDMA 0.3970.04 0.6670.05*** 0.4570.05 0.9370.14** 0.4070.04 2.2770.17***,a
Urea 4.0670.41 5.2970.38 4.7770.42 9.7671.71* 4.2870.40 24.272.2***,a
no–60 ml/min/1.73 m2, GFR range from normal to 60 ml/min/1.73 m2; comparisons were performed by means of a t-test.
ADMA, asymmetrical dimethylarginine; Arg, arginine; ArgA, argininic acid; CT, creatine; CTN, creatinine; G, guanidine; GAA, guanidinoacetic acid; GSA, guanidinosuccinic acid;
g-GBA, g-guanidinobutyric acid; b-GPA, b-guanidinopropionic acid; Harg, homoarginine; aKetodGVA, a-keto-d-guanidinovaleric acid; MG, methylguanidine; a-NAA,
a-N-acetylarginine; SDMA, symmetrical dimethylarginine.
*Po0.05; **Po0.01; ***Po0.001.
aWhen the normality of data distribution failed, a Mann–Whitney rank sum test was run.
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Urine. Urinary excretion of GSA and MG was progres-
sively increased in homozygous and heterozygous rats (Table
3a and b). Urinary excretion of GAA, however, was
progressively decreased in homozygous and heterozygous
animals. ADMA and SDMA excretion was decreased in
homozygous rats, but increased in oldest heterozygous rats.
CTN excretion was increased in youngest heterozygous rats
but decreased in homozygous rats toward end-stage renal
disease. The excretion of the other GCs had a tendency to
decrease in homozygous rats toward end-stage renal failure;
in heterozygous rats, however, they tended to be unchanged.
Kidney. In kidneys of homozygous PKD rats, urea, GSA,
CTN, and MG increased progressively; a-Keto-d-GVA was
also increased in younger rats (Table 4a and b). Within the
studied heterozygous groups, retention of these compounds
was mostly seen in kidneys of oldest rats. g-GBA and to a
lesser extent G were increased in kidney tissue of most
heterozygous rats, which was not observed in the homo-
zygous group.
Clearly, decreased levels of kidney CT, GAA, b-guanidi-
nopropionic acid (b-GPA), Arg, Harg, and ADMA during
renal failure were observed in homozygous rats. Similar
observations were made for CT, GAA, b-GPA, and Harg in all
heterozygous rats and for Arg only in younger heterozygous
rats. A trend for a decrease of ADMA in kidney of
heterozygous rats was also seen.
Table 1b | GCs (lmol/24 h) and urea (mmol/24 h) in urine of PKD patients and controls
Urine
Controls
n=8
GFR: no-60 ml/min/1.73 m2
n=8
controls
n=7
GFR: 20–60 ml/min/1.73 m2
n=7
controls
n=10
GFR: o20 ml/min/1.73 m2
n=10
aKetodGVA 13.071.71 8.2871.72 11.272.71 10.272.23 10.171.11 3.9170.68***
GSA 29.672.6 29.374.6 28.972.12 53.6710* 29.474.4 150724***
CT 8427375 6747227 3427108 6247380 6017274 212764
GAA 382773 324756 305748 255772 337756 38.477.1***,a
a-NAA 29.273.6 2373.1 29.973.5 29.378.4 23.872.8 12.072.0**
ArgA 6.770.9 5.371.0 7.371.5 9.772.0 6.070.8 4.470.9
b-GPA oDL oDL-0.3 oDL oDL-1.7 oDL oDL-1.4
CTN 1058771001 764471411 1105871454 1269573402 99937881 946571195
g-GBA 9.673.1 7.871.7 17.573.6 14.174.9 12.173.0 3.7170.68*
Arg 1372.7 1172.2 2575.3 2075.9 2474.4 2575.4
Harg oDL-5.8 oDL-12 oDL-2.2 oDL-6.7 oDL-2.9 oDL-2.3
G 1371.0 1071.4 1371.3 2076.6 1171.2 1872.5*
MG 4.2/0.34 3.770.55 8.171.9 1172.8 5.070.8 5278.0***
ADMA 44.471.9 53.379.5 41.877.0 43.9716 43.273.2 9.6471.7***
SDMA 38.672.4 50.479.1 39.874.7 65.0723 37.272.5 31.574.8
Urea 284735 233734 308736 367765 277742 262737
no–60 ml/min/1.73 m2, GFR range from normal to 60 ml/min/1.73 m2; comparisons were performed by means of a t-test.
ADMA, asymmetrical dimethylarginine; Arg, arginine; ArgA, argininic acid; CT, creatine; CTN, creatinine; DL, detection limit; G, guanidine; GAA, guanidinoacetic acid; GSA,
guanidinosuccinic acid; g-GBA, g-guanidinobutyric acid; b-GPA, b-guanidinopropionic acid; Harg, homoarginine; aKetodGVA, a-keto-d-guanidinovaleric acid; MG,
methylguanidine; a-NAA, a-N-acetylarginine; SDMA, symmetrical dimethylarginine.
*Po0.05; **Po0.01; ***Po0.001.
aWhen the normality of data distribution failed, a Mann–Whitney rank sum test was run.
Table 2a | GCs (lM) and urea (mM) in plasma of homozygous PKD/Mhm rats and controls
Age
15 days 20 days 23 days
Genotype CO n=11 HO n=11 CO n=11 HO n=11 CO n=12 HO n=12
aKetodGVA 0.1770.01 0.6870.07***,a 0.2370.03 1.3170.16*** 0.3770.03 0.8370.06***
GSA 0.0970.01 3.0371.4***,a 0.0970.01 8.2372.4***,a 0.0770.01 19.271.2***,a
CT 236718 288729 162711 123717 190714 132717*
GAA 5.8070.22 7.6670.71*,a 5.9770.31 5.3970.61 5.5370.32 2.2770.22***
a-NAA 2.1270.08 1.8170.16 2.1370.08 2.0170.15 1.9270.12 1.7570.10
ArgA o0.007–0.08 0.1070.01 0.0670.00 0.1370.01*** o0.007–0.08 0.2070.02
b-GPA 0.0570.00 0.0670.01 0.0470.00 o0.007-0.07 o0.007–0.07 o0.007–0.03
CTN 15.370.63 39.272.4*** 18.671.1 79.777.3***,a 1370.55 163711***,a
g-GBA 0.2170.03 0.5170.10* 0.4770.04 1.2270.23***,a 1.0770.14 2.3270.32**
Arg 20575.2 225716 218710 16378.8*** 209711 11176.1***
Harg 7.8570.49 7.7070.77 7.7670.20 5.5070.56*** 3.8070.45 2.4170.41*
G o0.03-0.6 0.4570.08 0.1470.01 0.7970.09*** 0.2970.02 1.2670.05***
MG o0.01 o0.01–0.1 0.0570.00 0.1970.04*** o0.01 0.6570.08
ADMA 1.4970.07 1.7770.07** 1.6070.03 1.5370.04 1.5070.07 1.2370.07*
SDMA 0.6970.04 2.1270.08*** 0.8870.03 2.6770.14*** 0.6070.05 3.6870.09***
Urea 5.3570.16 39.776.8***,a 4.8570.17 53.575.6***,a 5.2470.19 88.574.8***,a
CO, controls; HO, homozygous.
Full name of the compounds studied can be found in Table 1b.
*Po0.05; **Po0.01; ***Po0.001 difference between genotypes per age group; comparisons were performed by means of a t-test.
aWhen the normality of data distribution failed, a Mann–Whitney rank sum test was run.
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Liver. As in the kidney, increased levels of urea, GSA, and
CTN were also observed in the liver of homozygous and
heterozygous rats (Table 5a and b). The increases of a-Keto-
d-GVA, argininic acid, g-GBA, G, MG, ADMA, and SDMA
seen in the liver of homozygous PKD animals were also
observed, to a certain extent, in the liver of heterozygous rats.
Decreased GAA levels were seen only in the liver of
homozygous rats with end-stage renal failure. The other
studied GC levels in the liver of homozygous and hetero-
zygous rats are similar to those observed in controls.
Brain. Increase of urea and GSA with renal failure was
also present in brains of homozygous and heterozygous
animals (Table 6a and b). Brain concentration of SDMA
increased progressively with kidney dysfunction in homo-
zygous rats. On the other hand, it should be stressed that the
ADMA levels of the homozygous and heterozygous rats were
not significantly higher than those found in control rats. In
contrast to the kidney and liver, brain CTN concentration
was unchanged in homozygous and decreased with renal
failure in heterozygous rats. Brain concentration of Arg was
decreased in homozygous rats with end-stage renal failure
and oldest heterozygous rats. The levels of the other GCs
found in homozygous and heterozygous rats are comparable
(metabolically) with corresponding control levels.
Table 2b | GCs (lM) and urea (mM) in plasma of heterozygous PKD/Mhm rats and controls
Age
2 months 10 months 18 months
Genotype CO n=6 HE n=8 CO n=6 HE n=7 CO n=6 HE n=6
aKetodGVA 0.2170.02 0.3070.01** o0.01-0.2 0.2370.03 0.1370.01 0.4570.12**,a
GSA 0.0770.01 0.1770.01*** 0.1270.01 0.3270.02*** 0.1570.02 5.0172.6**,a
CT 215720 20476.0 506723 224717*** 409731 179773*
GAA 5.270.19 5.070.16 5.370.43 3.970.30* 5.670.65 2.670.64**
a-NAA 1.770.12 1.770.07 1.570.05 1.470.05 1.470.12 1.770.18
ArgA o0.007 o0.007–0.05 o0.007–0.04 0.0370.00 o0.007 0.1270.03
b-GPA o0.007-0.07 0.0770.00 0.0870.01 0.1270.00** 0.1270.02 0.1670.03
CTN 1570.75 3170.70*** 3471.8 4772.0*** 3472.2 165744*
g-GBA 0.5970.06 1.570.19** 0.2870.09 1.170.16** 0.3270.06 3.570.46***
Arg 16674.2 20474.7*** 138713 17077.4* 138711 145726
Harg 1.670.10 1.770.06 1.370.13 1.070.03* 0.8470.14 0.8170.11
G 0.2770.03 0.3670.02* o0.03-0.2 0.3070.02 0.2470.03 1.2970.27**
MG o0.01 o0.01 o0.01 o0.01–0.03 o0.01 0.2770.14
ADMA 1.0970.05 0.8170.03*** 0.5570.04 0.5670.02 0.5670.03 0.7370.12
SDMA 0.5470.01 0.3670.01*** 0.3470.04 0.3570.02 0.3970.03 0.9370.17*
Urea 3.970.34 9.870.37*** 6.370.44 1470.46*** 5.270.35 3077.7**,a
Full name of the compounds studied can be found in Table 1b.
CO, controls; HE, heterozygous.
*Po0.05; **Po0.01; ***Po0.001 difference between genotypes per age group; comparisons were performed by means of a t-test.
aWhen the normality of data distribution failed, a Mann–Whitney rank sum test was run.
Table 3a | GCs (lM) and urea (mM) in urine of homozygous PKD/Mhm rats and controls
Age
15 days 20 days 23 days
Genotype CO n=11 HO n=11 CO n=11 HO n=10 CO n=10 HO n=9
aKetodGVA 13.971.6 18.972.7 78.8714 13.672.0*** 86.3717 6.2370.53***
GSA 4.7570.46 43.5720***,a 9.5471.1 48.977.5***,a 8.1071.3 70.374.5***
CT 170737 5967143** 65.7710 26.473.5** 1657103 22.372.3
GAA 365749 141714*** 585788 31.576.3***,a 5597102 10.272.2***,a
a-NAA 14.971.8 23.972.2** 27.975.4 14.471.2* 36.676.3 7.2171.2***
ArgA 0.5870.08 0.9870.09** 2.0970.33 0.8670.06** 3.7870.67 0.9470.07***,a
b-GPA oDL-0.30 oDL-0.73 oDL-0.4 oDL-0.72 0.3470.05 oDL-0.86
CTN 909+/+84 882770 24917371 898733**,a 15697248 951765*
g-GBA 21.873.1 13.471.9* 160727 17.470.85***,a 394771 18.072.5***,a
Arg 26.072.4 34.177.1 74.4712 29.476.0** 95.7720 55.1716
Harg oDL-1.6 0.4870.03 2.6270.30 0.5170.03*** oDL-3.6 0.5370.03
G 5.8970.52 4.3170.26* 28.775.4 6.5370.71** 38.876.6 6.1870.49***,a
MG 1.4470.13 3.7070.46*** 2.270.5 8.8070.86***,a 2.0170.31 15.771.3***,a
ADMA 37.074.9 3.2370.44***,a 45.778.3 3.0070.06***,a 9.0171.3 2.0670.2***
SDMA 58.077.0 14.571.1*** 90.9714 14.570.7***,a 28.175.1 12.270.62*
Urea 126712 23278.7*** 230727 23476.8 278739 24275.8
Full name of the compounds studied can be found in Table 1b.
CO, controls; DL: detection limit; HO, homozygous.
*Po0.05; **Po0.01; ***Po0.001 difference between genotypes per age group; comparisons were performed by means of a t-test.
aWhen the normality of data distribution failed, a Mann–Whitney rank sum test was run.
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DISCUSSION
Patients with end-stage renal failure show altered GC
concentrations that probably contribute to their symp-
toms.4,11,12,27 This is the first study evaluating concentrations
of GCs in a population of renal insufficient individuals
consisting exclusively of PKD patients. In addition, altera-
tions of GC concentrations were studied for the first time in a
rat model for PKD and compared with the observations in
patients. As seen in humans with PKD, the PKD rat model
shows loss of renal function as a consequence of renal cyst
formation.22
Our observations in patients with PKD largely confirm
previous findings in patients with uremia due to different
etiologies.12 The increase of GSA to about 39 times in PKD
patients’ serum is comparable to the 38 times GSA increase
found by Marescau et al.12 Further, also the range of MG, G,
CTN, a-NAA, ADMA, and SDMA increases reported by
those authors were confirmed in the PKD patients studied
here. The significant decrease of serum GAA reported in the
uremic patient group including different etiologies12 was also
seen in the serum of the PKD patients studied here.
Urea and GSA, which is metabolically related to urea,28–30
were shown to be important retention solutes in the PKD rat
model. Their concentrations increased progressively with
renal failure in plasma and all tested tissues from homo-
zygous rats and in most heterozygous rats. The decreased
Table 3b | GCs (lmol/24 h) and urea (mmol/24 h) in urine of heterozygous PKD/Mhm rats and controls
Age
2 months 10 months 18 months
Genotype CO n=6 HE n=8 CO n=6 HE n=7 CO n=6 HE n=5
aKetodGVA 0.9870.08 0.5570.03*** 0.8170.07 0.5570.10 0.7170.15 0.4470.12
GSA 0.1570.01 0.4470.02*** 0.4070.03 0.9370.05*** 0.4070.07 1.5870.29**
CT 0.8970.08 1.1370.08 2.5170.74 1.6270.17 3.6072.1 1.1070.07
GAA 8.8670.88 5.1470.37*** 5.3470.96 4.0170.28 5.6471.3 1.6570.33*
a-NAA 0.7770.15 1.3170.04** 1.3270.20 1.2970.07 0.8270.26 0.9370.11
ArgA 0.0670.00 0.0770.00* 0.0770.01 0.0670.01 0.0470.01 0.0970.01***
b-GPA 0.0270.00 0.0370.00** 0.0770.01 0.0670.00 0.0570.01 0.0370.00
CTN 37.672.4 69.971.7*** 13677.9 16377.9* 129716 13873.7
g-GBA 6.4270.31 6.0270.12 5.9870.76 5.7270.36 5.2370.90 4.7270.27
Arg 1.3070.17 2.0370.37 0.6070.12 0.7770.13 0.6770.14 0.6270.03
Harg 0.0370.01 0.0170.00* oDL-0.05 0.0270.00 oDL-0.06 oDL
G 1.1370.06 1.4170.02*** 0.6770.10 1.0870.12* 0.6570.12 1.2970.11**
MG 0.0570.00 0.1870.00*** 0.0970.01 0.1870.01*** 0.0970.01 0.4770.10**
ADMA 0.0087 0.003 0.01370.001*,a 0.0370.00 0.0670.01* 0.0470.005 0.2270.05**
SDMA 0.1670.04 0.2270.01 0.0870.01 0.4470.04*** 0.0870.03 0.5170.04***
Urea 6.1370.45 9.8270.24*** 10.270.65 11.870.82 7.7171.1 12.870.96**
Full name of the compounds studied can be found in Table 1b.
CO, controls; DL: detection limit; HE, heterozygous.
*Po0.05; **Po0.01; ***Po0.001 difference between genotypes per age group; comparisons were performed by means of a t-test.
aWhen the normality of data distribution failed, a Mann–Whitney rank sum test was run.
Table 4a | GCs (nmol/g tissue) and urea (lmol/g tissue) in kidney of homozygous PKD/Mhm rats and controls
Age
15 days 20 days 23 days
Genotype CO n=8 HO n=11 CO n=8 HO n=11 CO n=8 HO n=12
aKetodGVA 1.4770.12 13.170.79*** 1.6970.22 9.7170.36*** 4.8770.59 6.7871.17
GSA 0.9570.04 23.378.0***,a 0.7070.09 35.177.5***,a 0.8870.08 47.572.9***,a
CT 1473765 474748*** 864732 208710*** 969748 197715***
GAA 299716 6176.9*** 27579.0 22.272.2*** 257728 12.171.2***a
a-NAA 24.470.82 16.771.3*** 18.871.5 14.470.61* 23.371.1 8.4771.0***
b-GPA 1.8570.08 0.4170.07*** 2.1070.08 0.4570.09*** 2.3570.11 0.4170.08***
CTN 15475.1 385740*** 206712 505716*** 11276.5 519728***
g-GBA 3.2770.37 5.6170.96 10.570.80 8.2070.42* 21.771.7 8.6471.3***
Arg 415718 11074.3*** 562731 9972.0***,a 515726 9376.3***
Harg 8.2570.57 2.1970.13*** 9.6070.36 1.9970.13*** 5.2270.61 1.2770.18***
G 2.7270.75 2.1970.29 2.0170.08 2.8370.12*** 4.1670.44 3.4870.27
MG oDL 1.3870.19 0.3770.05 4.2870.64***,a oDL 6.1770.35
ADMA 6.4470.45 1.9170.07*** 11.071.7 2.1270.15***,a 7.9470.83 1.4370.09***,a
SDMA 6.1670.38 7.7770.49* 9.8870.70 10.370.50 6.7470.37 7.6170.64**
Urea 19.871.9 52.278.8** 16.771.6 64.076.0***,a 30.473.8 87.174.5***
ArgA could not be determined in kidney as its concentration was around detection limit; comparisons were performed by means of a t-test.
Full name of the compounds studied can be found in Table 1b.
CO, controls; DL: detection limit; HO, homozygous.
*Po0.05; **Po0.01; ***Po0.001 difference between genotypes per age group.
aWhen the normality of data distribution failed, a Mann–Whitney rank sum test was run.
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removal of GSA as well as an increased synthesis because of
increased urea retention are probably involved. Also, CTN
was observed as an important retention product, with
increased concentrations in the plasma, kidney, and liver of
homozygous rats and in most heterozygous rats. Other
possibly important retained solutes (although not signifi-
cantly increased in all tissues) were G, MG, SDMA, and a-
Keto-d-GVA. In addition to decreased MG removal by the
kidneys, it is known that the formation of the CTN
degradation product MG is favored with a lowered GFR in
renal failure.31 Although the ADMA levels in the liver of
homozygous and heterozygous rats were approximately
doubled, ADMA was not retained in the plasma, kidney,
and brain of the model. Decreased concentrations of Arg and
GAA in the kidneys of PKD rats are probably the
consequence of their disturbed synthesis, which is known
to take place in the proximal tubules of the kidneys.32,33
Harg, CT, ADMA, and b-GPA were the other solutes
decreased in the kidney of PKD rats, which could also be
directly or indirectly related to the lowered kidney synthesis.
Can the rat model be used as a biochemical model for
human PKD? Increase of urea was observed in plasma and
Table 4b | GCs (nmol/g tissue) and urea (lmol/g tissue) in kidney of heterozygous PKD/Mhm rats and controls
Age
2 months 10 months 18 months
Genotype CO n=6 HE n=8 CO n=6 HE n=7 CO n=6 HE n=6
aKetodGVA 3.4570.22 1.1270.08*** 1.8670.42 2.3870.39 1.7270.13 7.7871.4***
GSA 0.9370.07 1.2070.04** 1.4970.20 2.6270.36* 1.4270.12 16.274.5**,a
CT 12997129 806724*** 40817581 532714*** 29337375 6347131***
GAA 265716 10677.2*** 25775.5 81.473.2*** 243714 39.0713***
a-NAA 12.270.43 6.2070.40*** 6.9470.88 7.7671.04 5.1071.35 1572.91*
b-GPA 4.3470.19 2.7870.14*** 9.2370.74 2.6670.13*** 10.171.3 1.7270.15***
CTN 186711 18678.1 405772 307740 328719 686790**
g-GBA 12.871.3 20.171.4** 7.4472.4 19.172.2** 7.5572.3 35.676.3**
Arg 583735 331746** 436723 262725*** 434739 472769
Harg 3.5970.21 2.2870.09*** 3.4370.40 1.4270.10*** 2.7370.56 1.1070.13*
G 4.2370.61 3.5970.30 2.4170.33 4.7370.46** 3.6770.62 5.2870.35*
MG oDL-0.23 0.1870.01 0.2970.04 0.3670.06 0.2870.04 3.6571.00**
ADMA 9.3070.58 3.7671.2** 3.5270.35 2.2270.54 4.6370.84 2.3470.16*
SDMA 5.5070.46 2.0970.20*** 1.7270.25 1.6270.13 2.3470.44 4.5670.68*
Urea 19.972.9 22.171.3 24.974.3 24.572.4 26.673.3 40.276.1
ArgA could not be determined in kidney as its concentration was around detection limit; comparisons were performed by means of a t-test.
Full name of the compounds studied can be found in Table 1b.
CO, controls; DL: detection limit; HE, heterozygous.
*Po0.05; **Po0.01; ***Po0.001 difference between genotypes per age group.
aWhen the normality of data distribution failed, a Mann–Whitney rank sum test was run.
Table 5a | GCs (nmol/g tissue) and urea (lmol/g tissue) in liver of homozygous PKD/Mhm rats and controls
Age
15 days 20 days 23 days
Genotype CO n=8 HO n=11 CO n=8 HO n=11 CO n=8 HO n=12
aKetodGVA oDL-0.3 0.7670.07 0.3370.02 0.8370.06*** 0.4770.05 0.8970.07***
GSA 2.2170.23 53.3717***,a 6.3571.1 82.5710***,a 4.5770.32 12677.4***,a
CT 408723 497788 221718 198721 262721 239743
GAA 16.070.84 16.171.2 11.170.62 10.270.68 14.772.5 5.0870.39***
ArgA oDL-0.2 0.7270.05 0.2770.01 1.1370.10***,a oDL-0.2 2.1470.08
b-GPA 9.3270.43 17.271.4*** 8.4470.42 9.6871.1 12.470.93 14.671.0
CTN 45.872.8 58.774.8 23.170.69 82.2711***,a 44.674.9 16078.7***
g-GBA 52.372.8 81.7713 92.479.0 231725*** 266713 501765**
Arg 49.675.2 33.475.6 18.170.92 19.671.9 21.771.8 19.772.0
Harg 11.170.64 13.971.8 9.2170.47 12.671.7 5.3670.82 7.9271.3
G 1.4870.25 10.974.6*,a 1.1570.14 11.473.4***,a 1.8170.48 16.175.7***,a
MG oDL 0.2470.03 0.2670.02 0.6770.15**,a oDL 2.4970.23
ADMA 1.0270.09 2.0170.23** 1.5470.11 1.4570.10 0.9570.04 1.6370.09***,a
SDMA 2.4970.08 6.5370.59*** 1.8570.06 8.3170.51***,a 1.2770.06 16.270.66***
Urea 5.3170.20 27.674.7***,a 5.5070.25 40.874.9***,a 5.3470.17 64.473.3***,a
a-NAA could not be determined in liver because of analytical restrictions; comparisons were performed by means of a t-test.
Full name of the compounds studied can be found in Table 1b.
CO, controls; DL: detection limit; HO, homozygous.
*Po0.05; **Po0.01; ***Po0.001 difference between genotypes per age group.
aWhen the normality of data distribution failed, a Mann–Whitney rank sum test was run.
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tissues of PKD rats. Range of increase of urea in plasma of
15-day-old homozygous (7 ) and heterozygous (2–6 )
rats was comparable with increase in serum of patients with a
GFR below 60 ml/min/1.73 m2 (2–6 ). Increase of GSA was
obvious in plasma, urine, and tissues of homozygous and
heterozygous animals and was also observed in serum and
urine of PKD patients. GSA increased about 33 times in the
plasma of youngest homozygous and oldest heterozygous
rats, which was similar to the 39 times increase of GSA in
serum of patients with GFR below 20 ml/min/1.73 m2. The
increase of plasma GSA seen in heterozygous rats aged 2 and
10 months was in the same order of magnitude as the
increase in serum of patients with a GFR between 20 and
60 ml/min/1.73 m2. CTN increase in the plasma, kidney, and
liver of homozygous and heterozygous PKD rats was also
present in patients’ serum. The 2 and 8 times increase of CTN
in serum of patients with a GFR of 20–60 and o20 ml/min/
1.73 m2, respectively, was comparable to the increase in
plasma of heterozygous and homozygous rats (2 to 12 ).
Increased MG and G in homozygous and heterozygous rats
was observed in serum of patients. Increased SDMA values in
the plasma, liver, and brain of homozygous and oldest
heterozygous rats were also seen in serum of patients, and
degrees of increase in blood were in the same order of
Table 5b | GCs (nmol/g tissue) and urea (lmol/g tissue) in liver of heterozygous PKD/Mhm rats and controls
Age
2 months 10 months 18 months
Genotype CO n=6 HE n=8 CO n=6 HE n=7 CO n=6 HE n=6
aKetodGVA oDL-0.5 0.3870.04 0.3070.04 0.5970.05*** oDL-0.4 1.1770.16
GSA 4.4270.51 11.170.42*** 15.371.43 23.871.5** 12.771.3 53.6714**,a
CT 356735 324711 886770 283717**,a 726759 6287399
GAA 8.5170.57 8.2070.65 6.5871.4 10.172.1 4.3370.70 4.6370.63
ArgA oDL-0.3 0.5370.04 oDL-0.2 0.5370.05 oDL-0.3 1.0370.25
b-GPA 17.771.1 25.471.0*** 43.173.7 38.173.3 50.876.5 79.5733
CTN 43.972.4 72.074.6*** 43.972.5 76.876.2*** 63.376.4 179746*
g-GBA 106711 163711** 51.7715 228715*** 71.8728 8167182**
Arg 13.971.6 11.771.2 10.471.1 14.471.2* 12.171.0 16.572.3
Harg 2.6370.19 3.5170.17** 3.9070.32 2.6870.19** 2.2370.24 2.0770.22
G 3.3871.4 7.5971.6 1.6170.16 5.7472.4**,a 1.4470.19 4.2370.99*
MG oDL oDL oDL oDL oDL oDL-3.8
ADMA 0.8070.08 1.9570.16*** 0.8570.09 2.6570.38** 1.0670.24 2.3070.38*
SDMA 1.2570.19 1.9170.10** 2.0670.29 4.9771.3 2.1670.26 4.1771.1
Urea 4.3370.27 8.3970.28*** 6.0570.26 11.670.83*** 5.2170.32 22.876.0**,a
a-NAA could not be determined in the liver because of analytical restrictions; comparisons were performed by means of a t-test.
Full name of the compounds studied can be found in Table 1b.
CO, controls; DL: detection limit; HE, heterozygous.
*Po0.05; **Po0.01; ***Po0.001 difference between genotypes per age group.
aWhen the normality of data distribution failed, a Mann–Whitney rank sum test was run.
Table 6a | GCs (nmol/g tissue) and urea (lmol/g tissue) in brain of homozygous PKD/Mhm rats and controls
Age
15 days 20 days 23 days
Genotype CO n=8 HO n=11 CO n=11 HO n=11 CO n=8 HO n=12
GSA 0.2270.02 1.2770.50***,a 0.3670.03 1.8470.47***,a 0.2170.01 2.8970.26***
CT 75457134 78697373 71487211 81707333*,a 87297157 90717162
GAA 5.4170.37 4.7570.39 5.1870.20 3.5270.21*** 4.0970.25 4.0370.20
a-NAA 2.3170.18 2.9570.21* 2.3070.08 2.8270.30 5.1570.29 2.1970.10***
ArgA 0.2370.01 0.3770.04** 0.2970.02 0.4370.02*** 0.6170.04 0.5270.02*
b-GPA 0.4070.03 0.3770.02 0.3970.01 0.3470.02 0.4570.03 0.3470.02**
CTN 81.7712 68.8710 92.278.1 75.476.5 87.778.7 86.2712
g-GBA 18.672.4 21.970.45 19.570.83 20.370.85 22.971.7 19.070.57*
Arg 172711 16279.1 17073.7 16375.1 29379.6 149711***
Harg 5.3070.49 6.0570.55 5.6070.18 5.8670.72 4.6270.53 3.3070.46
G oDL-1.8 3.0471.2 0.5470.03 2.6370.66*,a oDL-5.3 6.4672.3
MG oDL oDL-0.2 0.3270.06 oDL-0.2 oDL 0.3170.05
ADMA 0.5470.03 0.5870.03 0.5570.02 0.4770.03* 0.4570.04 0.4270.05
SDMA 0.8570.06 1.5270.06*** 0.6570.03 2.1970.16*** 0.5670.04 3.7970.21***
Urea 4.4870.19 26.474.6***,a 4.5470.31 38.774.0***,a 4.4370.09 58.872.8***,a
a-Keto-d-GVA could not be determined in brain because of coelution of an unknown compound; comparisons were performed by means of a t-test.
Full name of the compounds studied can be found in Table 1b.
CO, controls; DL: detection limit; HO, homozygous.
*Po0.05; **Po0.01; ***Po0.001 difference between genotypes per age group.
aWhen the normality of data distribution failed, a Mann–Whitney rank sum test was run.
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magnitude. The increases of blood a-Keto-d-GVA and g-GBA
levels observed in the rat model were seen, as well in the
studied patients. The significantly decreased concentration of
plasma GAA seen at end-stage renal disease in homozygous
and oldest heterozygous rats was also observed in serum of
patients with lowest GFR. Moreover, decreased excretion of
GAA observed in homozygous and heterozygous rats did
correspond with decreased excretion of GAA in patients with
lowest GFR. Furthermore, the serum Harg levels seen in the
PKD patient group decreased progressively with decreasing
GFR, similar to the gradual decrease of the Harg plasma
levels found in homozygous and heterozygous rats. It should
also be stressed that PKD patients with renal insufficiency to
a degree comparable to that of homozygous rats of 23 days
(just before dying) were not included into our study group as
end-stage renal failure patients are usually dialyzed at this
stage. This could be the reason why the significantly
decreased concentration of Arg and CT seen in plasma of
homozygous rats at end-stage renal failure was not observed
in the PKD patients studied here. Furthermore, differences
between rat and human metabolism have also to be kept in
mind and can possibly be related to the consistently increased
levels of ADMA seen in serum of PKD patients, which were
not observed in plasma of homozygous and heterozygous
rats.
Although not being the goal of this study (comparison of
the GC profile of a PKD rat model with the human
condition), the serum GC levels observed in dialyzed PKD
patients, just before a new dialysis session, are comparable to
those found in our non-dialyzed PKD patient group with a
GFR below 20 ml/min/1.73 m2 (Table 7). However, this does
not implicate that the retained GCs would not further
increase when the patients would not be dialyzed.
In general, increases of urea and some GCs (GSA, CTN, G,
MG, and SDMA) in blood of oldest heterozygous and
younger homozygous PKD rats were comparable with those
found in the studied human PKD population, especially in
patients with GFR below 60 ml/min/1.73 m2. Decreased levels
of plasma GAA seen at end-stage renal disease in homo-
zygous and oldest heterozygous rats were also observed in
serum of patients with GFR below 20 ml/min/1.73 m2.
Previously, our group reported GC levels in a surgical rat
model (80% nephrectomy) for renal failure.17,19 The degree
of increases (urea, GSA, CTN, G, MG, SDMA, a-Keto-d-
GVA, and g-GBA) seen in plasma of this surgical model is
Table 6b | GCs (nmol/g tissue) and urea (lmol/g tissue) in brain of heterozygous PKD/Mhm rats and controls
Age
2 months 10 months 18 months
Genotype CO n=6 HE n=8 CO n=6 HE n=7 CO n=6 HE n=6
GSA 0.1170.00 0.2570.01*** 0.1070.01 0.2070.01*** 0.1270.01 0.7170.26**,a
CT 88917184 96957205* 96207208 86147319* 92317245 7112791***
GAA 3.2670.10 2.9070.09* 4.4070.82 3.9770.16 3.1170.20 6.6370.79**
a-NAA 3.8870.26 3.4970.08 2.0370.13 8.5370.43*** 2.4270.23 1.6970.08*
ArgA 1.1970.10 1.1570.05 1.4470.17 1.6470.07 1.7070.16 1.4970.05
b-GPA 0.5170.04 0.3270.02*** 0.4370.04 0.5470.03 0.6370.04 0.6770.08
CTN 10878.2 66.075.3*** 90.079.0 56.072.9** 177721 52.775.8***
g-GBA 11.771.1 10.970.22 7.5870.66 9.2870.16* 8.6670.60 10.770.70*
Arg 21575.6 231725 16078.7 13575.1* 19179.5 123723*
Harg 1.6170.10 1.5770.05 1.01270.086 1.00970.088 0.8470.08 0.6670.06
G 1.8671.2 5.6772.0*,a 0.5270.05 2.7171.1**,a 1.8970.97 1.3470.40
MG oDL-0.24 oDL-0.33 oDL-0.22 0.1070.01 0.2570.02 0.1870.05
ADMA 0.2870.03 0.2870.03 0.1770.01 0.1770.03 0.2070.02 0.1670.03
SDMA 0.4470.10 0.3370.03 0.2570.01 0.2970.01* 0.3370.03 0.6170.16
Urea 2.6270.16 6.3070.32*** 3.0270.11 6.2670.48*** 2.9770.29 10.872.8**,a
a-Keto-d-GVA could not be determined in brain because of coelution of an unknown compound; comparisons were performed by means of a t-test.
Full name of the compounds studied can be found in Table 1b.
CO, controls; DL: detection limit; HE, heterozygous.
*Po0.05; **Po0.01; ***Po0.001 difference between genotypes per age group.
aWhen the normality of data distribution failed, a Mann–Whitney rank sum test was run.
Table 7 | GCs (lM) and urea (mM) in serum of non-dialyzed
PKD patients with a GFRo20 ml/min/1.73 m2 and in dialyzed
PKD patients
Serum
Non-dialyzed
PKD patients with GFR
o20 ml/min/1.73 m2 n=11
Dialyzed PKD
patients n=12
aKetodGVA 0.2270.03 0.3870.06
GSA 11.071.8 9.9671.5
CT 34.479.4 50.1712.4
GAA 1.8370.19 2.0870.23
a-NAA 0.8870.12 1.4370.15
ArgA 0.2870.04 0.39370.09
b-GPA o0.013 o0.013–0.05
CTN 519766 854776
g-GBA o0.013–0.1 0.1270.02
Arg 11479.9 10579.5
Harg 1.1670.11 0.9270.14
G 1.3470.16 1.770.1
MG 1.0170.46 3.470.7
ADMA 0.8570.06 0.7770.05
SDMA 2.2770.17 2.8670.27
Urea 24.272.2 18.571.0
Full name of the compounds studied can be found in Table 1b.
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similar to the one observed in plasma of older (10–18
months) heterozygous PKD rats. Referring to the decreased
CT, GAA, Arg, and Harg levels in plasma of our PKD rat
model, only the levels of CT were decreased in the
nephrectomized rat model.17 On the other hand, decreased
GAA levels in blood have been described in a nephrectomized
mouse18 and rabbit34 model for renal failure.
In conclusion, PKD patients show GC concentration
changes similar to those found in patients with uremia owing
to different etiologies. The PKD rat model shows, besides
similar disease characteristics with PKD patients, comparable
GC alterations. GC concentration changes in older hetero-
zygous rats and younger homozygous rats were largely within
the same range of those seen in humans with PKD. Studying
the progression of pathobiochemistry of GCs in PKD in a
relative short time is possible in homozygous rats; however, a
slower progression of this pathobiochemistry can be seen in
heterozygous rats.
MATERIALS AND METHODS
Clinical protocols were approved by the Institutional Review Boards.
All patients gave their written informed consent according to the
Declaration of Helsinki Principles. Animal experiments were carried
out in accordance with the European Communities Council
Directive (86/609/EEC) and the protocol was approved by the
Animal Ethics Committee of the University of Antwerp.
Sample collection and preparation
Patients. Fasting morning blood and 24 h urine was collected
from non-dialyzed patients with PKD. Blood was centrifuged
(1000 g, 41C, 10 min) to obtain serum. Patients were divided into
three different groups: GFR from normal to 60 ml/min/1.73 m2
(mean7standard error of the mean (s.e.m.): 105711 ml/min/
1.73 m2), including two male and seven female patients with age
ranging from 31 to 50 years; GFR from 20 to 60 ml/min/1.73 m2
(mean7s.e.m.: 4375.7 ml/min/1.73 m2), including three male and
four female patients with age ranging from 48 to 65 years; and
finally, GFR o20 ml/min/1.73 m2 (mean7s.e.m.: 1271.5 ml/min/
1.73 m2), including eight male and three female patients with age
ranging from 37 to 71 years. Four patients had a GFR lower than
10 ml/min/1.73 m2. GFR was calculated with the abbreviated
Modification of Diet in Renal Disease Study equation presented
by Levey et al.35 and Levy.36 For each group, age- and gender-
matched control subjects were included. Mean7s.e.m. GFR values
of the used control groups were, respectively, 130713, 102711,
and 11679 ml/min/1.73 m2. Control subjects were healthy
volunteers and individuals presenting with transient neurologic
complaints in whom after performing clinical and chemical
diagnostic tests, no neurologic, renal, hepatic, or metabolic disease
was diagnosed.
Rat model. A Sprague–Dawley rat model of PKD (Han:SPRD),
obtained from a breeding colony from Dr F Deerberg (Central
Institute for Laboratory animal breeding, Hannover, Germany) and
maintained by Dr Gretz (Medical Research Center, Mannheim,
University of Heidelberg),21,22 was used. Since 1997, the strain is
registered in the list of inbred strains of rats by MFW Festing as
PKD/Mhm (http://www.informatics.jax.org/external/festing/rat/
docs/PKD.shtml). Groups were aged 15, 20, and 23 days for the
homozygous animals and 2, 10, and 18 months for the heterozygous
PKD rats. Homozygous groups consisted of males as well as females
and heterozygous groups consisted of male rats only as they
manifest a significantly more severe form of the disease than
females.21,24 For each group, a comparable amount of Sprague–-
Dawley control rats with the same age and sex were included. All
animals had free access to tap water and were kept on a same
standard laboratory diet (ssniffs R/M, Soest, Germany) containing
19% protein. Animals were housed in a room maintained at 201C
with a 12-h light and 12-h dark cycle.
Plasma and 24 h urine, brain, kidney, and liver of all rats were
collected. Twenty-four hours before starting the urine collection,
one drop of a pentachlorophenol solution (5 mg/ml in 95% ethanol)
was added to the collection tube. Urine collection was done after
24 h stay in individual metabolic cages for heterozygous and age-
matched control rats. Afterwards, animals were anesthesized
(Nembutal: 60 mg/kg) and blood was collected by heart punction
in heparinized tubes and centrifuged to obtain plasma. The liver,
kidney, and brain were dissected. Free blood has been eliminated as
much as possible by washing in ice-cold saline and adsorption by
blotting paper. Thereafter, tissue was put immediately in liquid
nitrogen and kept together with the other samples at 701C until
analysis. From homozygous and age-matched control animals, urine
was taken from the bladder using an injection needle after anesthesia
(Nembutal), because they were too young to be kept in metabolic
cages.
For determination of GCs, plasma, serum, and urine were
deproteinized with 10% trichloroacetic acid and centrifuged for
10 min (20 800 g, 41C). For ADMA and SDMA determination, the
plasma, serum, and urine were deproteinized with 10% sulfosalicylic
acid and centrifuged for 10 min (20 800 g, 41C). Tissues were
homogenized in 30% trichloroacetic acid and centrifuged for 30 min
(20 800 g, 41C).
Determination of GCs and urea
Samples were analyzed on a cation exchange liquid chromatograph
(Biotronik Amino Acid Analyser (LC5001) Biotronik, Eppendorf,
Hamburg, Germany) with post-column ninhydrine fluorescence
detection as described earlier.28 With this method 13 GCs are
detected: a-Keto-d-GVA, GSA, CT, GAA, a-NAA, argininic acid,
b-GPA, CTN, g-GBA, Arg, Harg, G, and MG. ADMA and SDMA
were determined with a cation exchange liquid chromatograph
(Biotronik Amino Acid Analyser (LC6001) Biotronik, Eppendorf,
Hamburg, Germany) with post-column OPA fluorescence detection
as described earlier.12
Urea was determined using the method of Ceriotti.37
Statistics
Results were presented as mean7s.e.m. Comparison between GC
concentrations of PKD patients and age- and gender-matched
controls was made with t-test using the statistical software program
Sigma Stats version 2.0 (Jandel GmbH, 40699 Erkrath, Germany).
Statistical analysis of GC concentrations in rats was also performed
with t-test comparing controls and PKD/Mhm rats per age
group. When the normality test of data distribution failed, a
Mann–Whitney rank sum test was run. Correlations between GFR
and concentrations of GCs in patients were determined
with Pearson’s product moment correlation. Compounds with
concentrations below the detection limit could not be included in
the statistical analysis and correlation studies. A P-value of o0.05
was considered statistically significant. Statistical differences are
depicted in tables as follows: *Po0.05; **Po0.01; ***Po0.001.
Kidney International (2006) 69, 2003–2012 2011
A Torremans et al.: Guanidino compounds in human and rat PKD o r i g i n a l a r t i c l e
ACKNOWLEDGMENTS
We were supported by the Belgian Fund for Scientific Research-
Flanders (FWO Grant no.6. 0394.00), the Agreement between FWO
Flanders and Institute Born Bunge, University of Antwerp, Antwerp
Medical Research Foundation, and Neurosearch Antwerp. We grate-
fully thank Mss I Possemiers for technical assistance.
REFERENCES
1. Wilson P. Polycystic kidney disease. N Engl J Med 2004; 350: 151–164.
2. Ringoir S, Schoots A, Vanholder R. Uremic toxins. Kidney Int 1988;
33(Suppl 24): S4–S9.
3. Vanholder R, De Smet R. Pathophysiologic effects of uremic retention
solutes. J Am Soc Nephrol 1999; 10: 1815–1823.
4. Vanholder RC, Glorieux G, De Smet R, De Deyn PP. Low water-soluble
uremic toxins. Adv Ren Replace Ther 2003; 10: 257–269.
5. Hanai T, Inamaoto Y, Inamoto S. Chromatography of guanidino
compounds. J Chromatogr B 2000; 747: 123–138.
6. Ho¨rl W. Uremic toxins: new aspects. J Nephrol 2000; 13: S83–S88.
7. Brouns R, De Deyn PP. Neurological complications in renal failure: a
review. Clin Neurol Neurosurg 2004; 107: 1–16.
8. De Deyn PP, Macdonald R. Guanidino compounds that are increased in
cerebrospinal fluid and brain of uremic patients inhibit GABA and glycine
response on mouse neurons in cell culture. Ann Neurol 1990; 28: 627–632.
9. D’Hooge R, Pei Y, Marescau B, De Deyn PP. Behavioral toxicity of
guanidinosuccinic acid in adult and young mice. Toxicol Lett 1992; 64–65:
773–777.
10. D’Hooge R, De Deyn PP, Van de Vijver G et al. Uraemic guanidino
compounds inhibit gamma-aminobutyric acid-evoked currents in mouse
spinal cord neurones. Neurosci Lett 1999; 265: 83–86.
11. De Deyn PP, Saxena V, Abts H et al. Clinical and pathophysiological
aspects of neurological complications in renal failure. Acta Neurol Belg
1992; 92: 191–206.
12. Marescau B, Nagels G, Possemiers I et al. Guanidino compounds in serum
and urine of nondialysed patients with chronic renal insufficiency.
Metabolism 1997; 46: 1024–1031.
13. Vallance P, Leone A, Calver A et al. Endogenous dimethylarginine as an
inhibitor of nitric oxide synthase. J Cardiovasc Pharmacol 1992; 20:
S60–S62.
14. Faraci FM, Brian JE, Heistad DD. Response of cerebral blood vessels to an
endogenous inhibitor of nitric oxide synthase. Am J Physiol 1995; 269:
H1522–H1527.
15. Segarra G, Medina P, Ballester RM et al. Effects of some guanidine
compounds on human cerebral arteries. Stroke 1999; 30: 2206–2210.
16. Glorieux G, Dhondt A, Jacobs P et al. In vitro study of the potential role of
guanidines in leukocyte functions related to atherogenesis and infection.
Kidney Int 2004; 65: 1–9.
17. Levillain O, Marescau B, De Deyn PP. Guanidino compound metabolism in
rats subjected to 20 and 90% nephrectomy. Kidney Int 1995; 47: 464–472.
18. Al Banchaabouchi M, Marescau B, D’Hooge R et al. Biochemical and
histochemical changes in nephrectomized mice. Metabolism 1998; 47:
355–361.
19. Al Banchaabouchi M, Marescau B, Possemiers I et al. NG,NG-dimethylar-
ginine and NG,N0G-dimethylarginine in renal insufficiency. Pflu¨gers Arch-
Eur J Physiol 2000; 439: 524–531.
20. Gattone V, Grantham J. Understanding human cystic disease trough
experimental models. Semin Nephrol 1991; 11: 617–631.
21. Gretz N, Hocker A, Bauer S et al. Rat models of polycystic kidney disease.
Contrib Nephrol 1992; 97: 35–46.
22. Kaspareit-Rittinghausen J, Deerberg F, Wcislo A. Hereditary polycystic
kidney disease: adult polycystic kidney disease associated with renal
hypertension, renal osteodystrophy, and uremic enteritis in SPRD rats. Am
J Pathol 1991; 139: 693–696.
23. Bihoreau M, Ceccherini I, Browne J et al. Location of the first genetic
locus, PKDr1, controlling autosomal dominant polycystic kidney disease
in Han:SPRD. Hum Mol Genet 1997; 6: 609–613.
24. Gretz N, Ceccherini I, Kra¨nzlin B et al. Gender-dependent disease severity
in autosomal polycystic kidney disease of rats. Kidney Int 1995; 48:
496–500.
25. Cowley B, Gudapaty S, Kraybill A et al. Autosomal-dominant polycystic
kidney disease in the rat. Kidney Int 1993; 43: 522–534.
26. Scha¨fer K, Gretz N, Bader M et al. Characterization of the Han:SPRD rat
model for hereditary polycystic kidney disease. Kidney Int 1994; 46:
134–152.
27. De Deyn PP, D’Hooge R, Van Bogaert PP, Marescau B. Endogenous
guanidino compounds as uremic neurotoxins. Kidney Int 2001; 59:
S77–S83.
28. Marescau B, De Deyn PP, Qureshi I et al. The pathobiochemistry of uremia
and hyperargininemia further demonstrates a metabolic relationship
between urea and guanidinosuccinic acid. Metabolism 1992; 41:
1021–1024.
29. Natelson S, Sherwin J. Proposed mechanism for urea nitrogen
re-utilization: relationship between urea and proposed guanidine cycles.
Clin Chem 1979; 25: 1343–1344.
30. Marescau B, De Deyn PP, Holvoet J et al. Guanidino compounds in serum
and urine of cirrhotic patients. Metabolism 1995; 44: 584–588.
31. Wyss M, Kaddurah-Daouk R. Creatine and creatine metabolism. Physiol
Rev 2000; 80: 1107–1213.
32. Levillain O, Hus-Citharel A, Morel F, Bankir L. Localization of arginine
synthesis along rat nephron. Am J Physiol 1990; 259: F916–F923.
33. McGuire DM, Gross MD, Elde RP, Van Pilsum JF. Localization of L-arginine-
glycine amidinotransferase protein in rat tissues by immunofluorescence
microscopy. J Histochem Cytochem 1986; 34: 429–435.
34. Kuroda M. Study on impaired metabolism of guanidinoacetic acid in
chronic renal failure rabbits with special reference to impaired conversion
of arginine to guanidinoacetic acid. Nephron 1993; 65: 605–611.
35. Levey AS, Bosch JP, Lewis JB et al. A more accurate method to estimate
glomerular filtration rate from serum creatinine: a new prediction
equation. Ann Intern Med 1999; 130: 461–470.
36. Levey AS. Nondiabetic kidney disease. N Engl J Med 2002; 347:
1505–1511.
37. Ceriotti G. Ultramicro determination of plasma urea by reaction with
diacetylmonoxime-antipyrine without deproteinization. Clin Chem 1971;
17: 400–402.
2012 Kidney International (2006) 69, 2003–2012
o r i g i n a l a r t i c l e A Torremans et al.: Guanidino compounds in human and rat PKD
